Randomized, open-label, prospective study to evaluate the safety and efficacy of sofosbuvir plus daclatasvir or ravidasvir in Egyptian adults with COVID-19

开始日期2020-09-29

申办/合作机构

European Egyptian Pharmaceutical Industry

NCT04478448 / Completed临床1期

An Open Label Randomized, Single Dose, Two-way Crossover Bioequivalence Study to Determine the Bioequivalence of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries, Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan) in Healthy Human Volunteers Under Fasting Condition.

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Favipiravir from Flupirava 200 mg tablet (European Egyptian Pharmaceutical Industries, Egypt) versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan) in Healthy Human Volunteers Under Fasting Condition.

开始日期2020-08-13

申办/合作机构

Genuine Research Center - Grc

[+1]

NCT02675127 / Completed临床1期

Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition.

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Pharmaceutical Industries, Egypt) versus Daklinza 60 mg tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition

开始日期2015-12-01

申办/合作机构

Genuine Research Center - Grc

[+1]

100 项与 European Egyptian Pharmaceutical Industry 相关的临床结果

登录后查看更多信息

0 项与 European Egyptian Pharmaceutical Industry 相关的专利（医药）

登录后查看更多信息

项与 European Egyptian Pharmaceutical Industry 相关的文献（医药）

2023-06-01·International Journal of Nanoscience

Biological Applications of Aqueous CuInS Quantum Dots: Overview

作者: Fouad, M. ; Ali, Magdy ; Kamel, Ola A.

Quantum dots (QDs), a type of semiconductor nanomaterial, have drawn a lot of attention because of their exceptional optical characteristics and prospective uses in biology and medicine. However, the presence of heavy hazardous metals in typical QDs, such as Cd, Pb and Hg, has posed a significant obstacle to their use. Therefore, it is essential to look for a workable substitute that would be nontoxic and have comparable optical characteristics to the traditional QDs. It has been determined that ternary I–III–VI QDs are appropriate substitutes. They emit light in the near-infrared range and have adjustable optical characteristics. They are valuable in a variety of biological applications because of their optical characteristics and can be easily bioconjugated with biomolecules for targeted imaging. Therefore, this review concentrates on the most recent developments in the usage of aqueous CIS QDs in biological, bioconjugated with biomolecules, nanomedical and drug delivery system applications.

2023-02-01·International Journal of Nanoscience

A Review, Water-Soluble CuInS Quantum Dots, Strategies and Photoluminescence

作者: Kamel, Ola A. ; Fouad, M. ; Ali, Magdy

Water-soluble semiconductor quantum dots (QDs) have become a unique field of materials science with great potential for applications in biomedical and optoelectronic devices. However, the more stable and bright QDs are the conventional QDs that contain toxic heavy metals such as Pb, Cd and Hg or the QDs that were synthesized in an organic phase. Hence, it is important to find an alternative material with similar optical properties and low cytotoxicity among these materials. Recently, hydrophilic CuInS2 (CIS) QDs have attracted a lot of interest due to their direct bandgap in the infrared region, large optical absorption coefficient, hydrophilicity, low cost and low toxic composition. These factors make them a good material for biomedical applications. This review starts with the origin characteristics of CIS QDs followed by various synthetic strategies, including synthesis in aqueous solvents and transformation from organic phase to water-soluble phase QDs. Then the tuning of their optical properties is discussed. The review then considers the strategies to improve the photoluminescence performances of CIS QDs.

2021-01-01·Drug Delivery2区 · 医学

Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules

2区 · 医学

ArticleOA

作者: El-Moslemany, Riham M. ; Ramadan, Alyaa A. ; El-Sheridy, Nabila A. ; Helmy, Maged W. ; El-Khordagui, Labiba K.

Itraconazole (ITC), a well-tolerated antifungal drug, exerts multiple anticancer effects which justified its preclinical and clinical investigation as potential anti-cancer agent with reduced side effects. Enhancement of ITC anti-cancer efficacy would bring valuable benefits to patients. We propose herein lipid nanocapsules (LNCs) modified with a subtherapeutic dose of miltefosine (MFS) as a membrane bioactive amphiphilic additive (M-ITC-LNC) for the development of an ITC nanoformulation with enhanced anticancer activity compared with ITC solution (ITC-sol) and unmodified ITC-LNC. Both LNC formulations showed a relatively small size (43-46 nm) and high entrapment efficiency (>97%), though ITC release was more sustained by M-ITC-LNC. Cytotoxicity studies revealed significantly greater anticancer activity and selectivity of M-ITC-LNC for MCF-7 breast cancer cells compared with ITC-sol and ITC-LNC. This trend was substantiated by in vivo findings following a 14 day-treatment of murine mammary pad Ehrlich tumors. M-ITC-LNC showed the greatest enhancement of the ITC-induced tumor growth inhibition, proliferation, and necrosis. At the molecular level, the tumor content of Gli 1, caspase-3, and vascular endothelial growth factor verified superiority of M-ITC-LNC in enhancing the ITC antiangiogenic, apoptotic, and Hedgehog pathway inhibitory effects. Finally, histopathological and biochemical analysis indicated greater reduction of ITC systemic toxicity by M-ITC-LNC. Superior performance of M-ITC-LNC was attributed to the effect of MFS on the structural and release properties of LNC coupled with its distinct bioactivities. In conclusion, MFS-modified LNC provides a simple nanoplatform integrating the potentials of LNC and MFS for enhancing the chemotherapeutic efficacy of ITC and possibly other oncology drugs.

100 项与 European Egyptian Pharmaceutical Industry 相关的药物交易

登录后查看更多信息

100 项与 European Egyptian Pharmaceutical Industry 相关的转化医学

登录后查看更多信息